---
title: "CHAIN BRIDGE I | 10-K: FY2025 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281417424.md"
datetime: "2026-04-01T20:04:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281417424.md)
  - [en](https://longbridge.com/en/news/281417424.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281417424.md)
generator: "portal-rs"
---

# CHAIN BRIDGE I | 10-K: FY2025 Revenue: USD 0

Revenue: As of FY2025, the actual value is USD 0.

EPS: As of FY2025, the actual value is USD -0.22.

EBIT: As of FY2025, the actual value is USD -1.074 M.

### Segment Revenue

The Company, Chain Bridge I, is a blank check company that has not generated any operating revenues to date and does not expect to until it completes its initial business combination .

### Operational Performance

#### Net Loss

-   For the year ended December 31, 2025: - $1,300,000 .
-   For the year ended December 31, 2024: - $1,400,000 .

#### Loss from Operations

-   For the year ended December 31, 2025: - $956,080 .
-   For the year ended December 31, 2024: - $2,182,923 .

#### General and Administrative Expenses

-   For the year ended December 31, 2025: $836,080 .
-   For the year ended December 31, 2024: $2,062,923 .

#### General and Administrative Expenses - Related Party

-   For the year ended December 31, 2025: $120,000 .
-   For the year ended December 31, 2024: $120,000 .

#### Change in Fair Value of Derivative Liabilities

-   For the year ended December 31, 2025: - $469,670 .
-   For the year ended December 31, 2024: $24,260 .

#### Change in Fair Value of Contingently Issuable Private Placement Warrants

-   For the year ended December 31, 2025: - $24,495 .
-   For the year ended December 31, 2024: $1,265 .

#### Interest Expense - Debt Issuance Cost

-   For the year ended December 31, 2025: - $78,066 .
-   For the year ended December 31, 2024: $0 .

#### Income from Investments Held in Trust Account

-   For the year ended December 31, 2025: $195,590 .
-   For the year ended December 31, 2024: $733,829 .

### Cash Flow

#### Net Cash Used in Operating Activities

-   For the year ended December 31, 2025: - $763,581 .
-   For the year ended December 31, 2024: - $925,535 .

#### Net Cash Provided by Investing Activities

-   For the year ended December 31, 2025: $4,714,427 .
-   For the year ended December 31, 2024: $40,805,003 .

#### Net Cash Used in Financing Activities

-   For the year ended December 31, 2025: - $3,690,189 .
-   For the year ended December 31, 2024: - $39,753,768 .

#### Net Change in Cash

-   For the year ended December 31, 2025: $260,657 .
-   For the year ended December 31, 2024: $125,700 .

### Liquidity and Financial Position

#### Cash on Hand

-   As of December 31, 2025: $390,255 .
-   As of December 31, 2024: $129,598 .

#### Working Capital Deficit

-   As of December 31, 2025: - $808,537 .

#### Investments Held in Trust Account

-   As of December 31, 2025: $766,224 .
-   As of December 31, 2024: $5,285,060 .

#### Outstanding Notes (as of December 31, 2025)

-   Exchange Note – related party: $368,680 .
-   Bridge Financing Note: $1,023,235 .
-   Senior Note, net: $1,078,066 .

#### Class A Ordinary Shares Subject to Possible Redemption

-   As of December 31, 2025: 62,590 shares at approximately $12.242 per share, totaling $766,224 .
-   As of December 31, 2024: 455,736 shares at approximately $11.377 per share, totaling $5,185,060 .

### Outlook/Guidance

The Company must consummate an initial Business Combination by November 15, 2026, or it will cease operations, redeem public shares, and liquidate . This liquidity condition and mandatory liquidation date raise substantial doubt about its ability to continue as a going concern . The Company aims to comply with SEC safe harbor criteria for SPACs, requiring a business combination to be identified within 18 months and completed within 24 months of its IPO to avoid being deemed an unregistered investment company .

### Related Stocks

- [CBRGF.US](https://longbridge.com/en/quote/CBRGF.US.md)

## Related News & Research

- [BRAIN Biotech cuts FY 2025/26 BRAINBiocatalysts outlook, sees revenue growth below FY 2024/25 level](https://longbridge.com/en/news/297129636.md)
- [Weekly Recap: H1 2024 net interest income +9% and £500m subordinated debt redemption](https://longbridge.com/en/news/296738894.md)
- [C21 Investments deregisters common shares under Exchange Act Section 12(g)](https://longbridge.com/en/news/297085290.md)
- [NetBrands files to deregister common stock under Exchange Act Section 12(g)](https://longbridge.com/en/news/297030615.md)
- [14:12 ETEstuary Rewrites Its Runtime for Agents at Enterprise Scale](https://longbridge.com/en/news/297077080.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**